Abstract:Background: Expert consensus on BRCA1/2 genetic testing and clinical application in Chinese breast cancer patients recommends that BRCA1/2 testing should be performed in those with clinical risk factors, such as an early onset, triple-negative breast cancer (TNBC) or family history of cancer. With the increasing application of multigene panels, testing for genes beyond BRCA1/2 has become more prevalent. However, the non- BRCA mutation status of Chinese high-risk breast cancer patients has not been fully explored. Methods: A total of 230 high-risk breast cancer patients from Fudan University Shanghai Cancer Center who had undergone peripheral blood germline 72 genes next-generation sequencing (NGS) from June 2018 to June 2020 were enrolled for retrospective analysis. The 72 genes include common hereditary breast cancer genes, such as homologous recombination repair (HRR) genes and other DNA damage repair genes. High-risk factors included: 1) TNBC; 2) male breast cancer; 3) primary bilateral breast cancer; 4) diagnosed with breast cancer at age less than or equal to 40 years; or 5) at least one first- and/or second-degree relative with BRCA -related cancer (breast or ovarian or prostate or pancreatic cancer). Results: The germline pathogenic or likely pathogenic mutation rate was 29.6% (68/230) in high-risk breast cancer patients. Among them, 44 (19.1%, 44/230) were identified as harboring BRCA1/2 mutation, and 28 (12.2%, 28/230) patients carried non- BRCA germline variants. Variants were detected in 16 non- BRCA genes, including PALB2 (5, 2.2%), ATM (4, 1.7%), RAD51D (3, 1.3%), TP53 (3, 1.3%), CHEK2 (2, 0.9%), FANCA (2, 0.9%) and ATR , BARD1 , BRIP1 , ERCC3 , HOXB13 , MLH1 , MRE11 , PMS2 , RAD51C , RAD54L (1, 0.4%). Besides, 22 (9.6%, 22/230) patients were non- BRCA HRR gene mutation (including ATM , ATR , BARD1 , BRIP1 , CHEK2 , FANCA , MRE11 , PALB2 , RAD51C RAD51D and RAD54L ) carriers. Among high-risk factors, family history showed a correlation with both BRCA ( p = 0.005) and non- BRCA HRR gene mutation status ( p = 0.036). In addition, TNBC showed a correlation with BRCA1 gene mutation status ( p = 0.038). However, other high-risk factors have not shown significantly related to BRCA1/2 , non- BRCA genes and non- BRCA HRR gene mutations ( p > 0.05). In addition, 312 unique variants of uncertain significance (VUS) were identified among 175 (76.1%, 175/230) patients and 65 different genes. Conclusions: Non- BRCA gene mutations are frequently identified in breast cancer patients with high risk factors. Family history showed a correlation with both BRCA ( p = 0.005) and non- BRCA HRR gene mutation status ( p = 0.036), so we strongly suggest that breast cancer patients with a BRCA -related family history receive comprehensive gene mutation testing in China, especially HRR genes, which are not only related to high risk of breast cancer, but also potentially related to poly ADP ribose polymerase inhibitor (PARPi) targeted therapy. The exact relationship of rare gene mutations to breast cancer predisposition and the pathogenicity of VUS need to be further investigated.

BRCA1 and BRCA2 mutations of 140 Chinese breast cancer patients with genetic high risk

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

The Prevalence of BRCA1 and BRCA2 Germline Mutations in High-Risk Breast Cancer Patients of Chinese Han Nationality: Two Recurrent Mutations Were Identified

Multicenter Cross-Sectional Screening of the BRCA Gene for Chinese High Hereditary Risk Breast Cancer Populations

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

[BRCA1 Germ Line Mutations in Chinese Early-Onset Breast Cancer Patients].

Mutational Analysis of BRCA1 and BRCA2 in Northwest Chinese Breast Cancer Patients.

Prevalence Of Brca1 And Brca2 Gene Mutations In Chinese Patients With High-Risk Breast Cancer

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

Identification of Recurrent Variants in BRCA1 and BRCA2 Across Multiple Cancers in the Chinese Population

The Spectrum of BRCA Mutations and Characteristics of BRCA-associated Breast Cancers in China: Screening of 2,991 Patients and 1,043 Controls by Next-Generation Sequencing.

[BRCA1/2 Gene Mutation in Chinese Familial Breast Cancer Patients: a Multi-Center Report of 115 Cases].

BRCA Germline Mutations in an Unselected Nationwide Cohort of Chinese Patients with Ovarian Cancer and Healthy Controls

Brca1 Germline Mutations and Tumor Characteristics in Chinese Women with Familial or Early-Onset Breast Cancer

BRCA1 1100delat is a Recurrent Mutation in Chinese Women with Familial Breast Cancer

Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions